AI for Early Identification of Breast Cancer – Efficient and Accurate Diagnosis

By Michael Awood

September 15, 2023

Breast cancer is the second leading cause of cancer death in women. Early identification can ease this to ensure early access to treatment. Developed nations have vast mammography screening programs, but interpreting the images is still hard. The accuracy of cancer detection varies widely among experts, and the potential for improvement is significant. False positives can lead to patient anxiety, unnecessary follow-up, and invasive diagnostic procedures. Sometimes screening cannot identify cancers until they are more advanced and less amenable to treatment.

Artificial Intelligence (AI) can overcome this challenge. Studies show it can outperform human experts in many medical image analysis tasks. This leads us to evaluate AI’s potential to augment the early identification process of breast cancer through high-quality images.

Researchers recently tested a new AI system that predicts breast cancer using large datasets from the UK and the USA. The system outperformed radiologists in daily predictions, according to the researchers. They confirmed these observations with an independently conducted reader study. The system could generalize across different screening populations and settings without additional training data.

The AI system might reduce the workload involved in the double-reading process used in the UK while preserving the standard of care. The system could also provide automated, immediate feedback in the screening setting. This technology can sort cases at the risk level, making it possible to screen efficiently even with a limited workforce.

Overall, the AI was better than radiologists at identifying breast cancer. These results held across two large datasets that represent different screening populations and practices. However, the optimal use of the AI system within clinical workflows remains to be determined.

Cover image taken from the journal article. 

Reference url

Recent Posts

NovoCare Pharmacy Wegovy
         

NovoCare and the Rise of Direct-to-Consumer Pharmaceutical Access

🌟 Did you know that access to essential obesity medications can significantly impact health outcomes?

NovoCare Pharmacy has just launched an innovative direct-to-patient delivery program for Wegovy (semaglutide) at a new, lower price of $499 per month for those uninsured or underinsured. This groundbreaking initiative not only enhances access to FDA-approved medication but also prioritizes patient safety by minimizing the risks of counterfeit alternatives.

Eager to learn more about how this is reshaping the obesity treatment landscape? Dive into the full article!

#SyenzaNews #HealthEconomics #MarketAccess

maternal child health Africa
   

Maternal Child Health in South Africa

🌍 How does economic growth truly impact maternal and child health in Africa?

While economic growth can lead to improved health outcomes, its effects are inconsistent and heavily influenced by socio-economic factors. Key elements like female education and effective governance are essential for maximizing these benefits.

Dive into our latest article to uncover the complexities at play and the critical policy implications for enhancing health outcomes in the region.

#SyenzaNews #globalhealth #healthcarepolicy

tuberculosis burden children
   

Tackling the Tuberculosis Burden in Children: A Global Perspective

🌍 Did you know the global burden of tuberculosis (TB) among children has dropped significantly over the past three decades?

Our recent analysis reveals a remarkable 37.4% reduction in TB incidence and a staggering 71.7% decrease in deaths from 1990 to 2021. Yet, challenges persist, especially in low SDI regions where this public health threat continues to expose disparities in healthcare access and outcomes.

Look into the full article to explore these critical insights and the implications for future strategies in TB management.

#SyenzaNews #globalhealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.